CAS: 14686-13-6; Heptylene-2, Trans

上下游产品

CAS号1974-04-5 2-溴庚烷 | CAS号124582-25-8 (E)-1-tributyls... | CAS号74-88-4 碘甲烷 | CAS号2384-92-1 (3E)-hepta-1,3-diene | CAS号592-76-7 1-庚烯 | CAS号38334-98-4 6-Bromo-1-heptene | CAS号83180-27-2 2-(phenylsulfon... | CAS号16644-98-7 反-1-碘己烯 | CAS号62872-76-8 3-benzene sulfo... | CAS号110-43-0 2-庚酮 | CAS号6443-92-1 顺-2-庚烯 | CAS号123-05-7 2-乙基已基醛 | CAS号16630-91-4 2-methylheptanal | CAS号142-82-5 正庚烷 | CAS号19780-39-3 3-乙基-2-庚醇 | CAS号61110-99-4 dimethyl 2-buty...

📜1-庚烯置于c24H42N2Pru(1+)*f6P(1-)体系中,用 氘代丙酮 用作溶剂,化学反应 0.5H,以96%的收率获得反-2-庚烯
参考文献:在形式上16电子的cp *孺咪唑基取代的动态π键(κ 2-P,ñ)+催化剂允许惊人的速度增加(ë)-选择性monoisomerization烯烃的
标题:在形式上16电子的cp *孺咪唑基取代的动态π键(κ 2-P,ñ)+催化剂允许惊人的速度增加(ë)-选择性monoisomerization烯烃的
摘要:烯烃异构化可以是一种原子经济的方法,可用于生成范围广泛的用于合成的烯烃中间体,但是完全平衡的二取代内部烯烃的混合物通常包含大量的位置异构体和几何异构体(e和z).用于烯烃异构化的大多数经典催化剂体系都难以动力学控制位置异构或e / Z异构.我们报告了配位不饱和,形式为16电子的cp * Ru催化剂5,它可促进线性1-烯烃同时向其内部类似物进行区域和立体选择性异构化,从而提供(e)-2-烯烃大于95%.由于无腈催化剂5比以前发表的含腈类似物2 + 2A快400倍以上,因此在15分钟至4小时内完成5个完全环境温度反应的0.1-0.5摩尔%非常合理的负载量.的uv-Vis,NMR,和计算研究描绘κ上膦作为hemilabile,四-电子给体的咪唑基片段2-P,ñ协调.对于第一次,我们显示直接的实验证据表明,Pn配体已经通过表征中间的cp *茹[η接受从基板的质子3-烯丙基] [κ 1-P)pn+
Doi:10.1021/acscatal.8B04345

专利信息

专利号:US-7247752-B2
优先权日:2004-10-01
标 题 :Methods for the synthesis of astaxanthin
发明人：LOCKWOOD SAMUEL F; TANG PENG CHO; NADOLSKI GEOFF; JACKSON HENRY L; FANG ZHIQIANG; DU YISHU; YANG MIN; GEISS WILLIAM; WILLIAMS RICHARD; BURDICK DAVID
权利人:CARDAX PHARMACEUTICALS INC
摘要:A method used for synthesizing intermediates for use in the synthesis of carotenoids and carotenoid analogs, and/or carotenoid derivatives. In some embodiments, the invention includes methods for synthesizing optically active intermediates useful for the synthesis of optically active carotenoids. Synthesis of optically active carotenoids, in one embodiment, may be accomplished by forming an optically active dihydroxy intermediate from ketoisopherone. The optically active dihydroxy intermediate may be converted into optically active astaxanthin derivatives.

专利号:US-2024228455-A1
优先权日:2021-04-27
标 题 :Synthesis of cbn and cbnv
发明人：KAVARANA MALCOLM J
权利人:TEEWINOT LIFE SCIENCES CORP
摘要:The invention includes chemical synthesis for preparing cannabinol (CBN) and cannabinovarin (CBNV). The process is suitable for inter alia the large-scale synthesis of pharmaceutical grade CBN and CBNV.

专利号:US-5200516-A
优先权日:1990-02-16
标 题:Synthesis of sugars from substituted and unsubstituted arene diols
发明人：HUDLICKY TOMAS
权利人:VIRGINIA TECH INTELL PROP
摘要:There are disclosed processes for the synthesis of substituted and unsubstituted arene diols useful in the further synthesis of sugars, sugar derivatives, chiral synthons or amino acids.

专利号:US-2008125587-A1
优先权日:2006-05-25
标 题 :Synthesis of triazole compounds that modulate HSP90 activity
发明人：CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
权利人:CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
摘要:The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: n n n n n n n n n n with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. n In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) n n n n n n n n n n with an oxidizing agent, thereby producing a compound of formula (IA). n The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: n n n n n n n n n n in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

专利号:US-10918627-B2
优先权日:2016-05-11
标 题:Convergent and enantioselective total synthesis of Communesin analogs
发明人：MOVASSAGHI MOHAMMAD; LATHROP STEPHEN PAUL; POMPEO MATTHEW W; CHANG WEN-TAU TIMOTHY
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:A highly convergent biomimetic synthesis of a complex polycyclic scaffold has been successfully implemented. From these efforts, compounds having a structure of Formula (I): n nor a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 1 -R 8 and m, n, r, s, t, and u are as defined herein, is provided. Methods of making such compounds are also disclosed as are methods for the treatment of cancer, various infectious diseases, and abnormal cardiovascular function.

专利号:US-7435861-B2
优先权日:2005-04-29
标 题 :Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
发明人：LOCKWOOD SAMUEL F; TANG PENG CHO; NADOLSKI GEOFF; JACKSON HENRY L; FANG ZHIQIANG; DU YISHU; YANG MIN; GEISS WILLIAM; WILLIAMS RICHARD; BURDICK DAVID
权利人:CARDAX PHARMACEUTICALS INC
摘要:A method for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The carotenoid analog, derivative, or intermediate may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include methods for synthesizing chemical compounds including an analog or derivative of a carotenoid. Carotenoid analogs or derivatives may include acyclic end groups. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.